Curexa Pharmacy, a provider of speciality compounding services in New Jersey, US, has bought a cleanroom from QleanAir Scandinavia.
QleanAir is a provider of clean indoor environment solutions and the agreement provides a 503(A) cleanroom suite for Curexa Pharmacy’s new location in Gilbert, Arizona in the US.
The 503(A) is the compounding pharmacy regulatory standard and as QleanAir provides cleanrooms that meet regulatory guidelines, the room should maintain a compliant state of control.
The project value is projected to cost approximately $2,500,000 (USD) and the new cleanroom suite is expected to be completed in 2024.
Amanda Myers, Chief Commercial Officer of QleanAir Scandinavia, said: “We are committed to working closely with Curexa’s pharmacy team to provide a compliant cleanroom solution that is technologically advanced and will ensure a safe environment focused on protecting products and processes necessary for compounding drugs.”
The 503(A) is the compounding pharmacy regulatory standard
“We are also excited to strategically strengthen our presence in the 503(A)-compounding marketplace with this partnership that also complements our successful US Hospital and Independent compounding business in the US today,” Myers concluded.
Mark Taylor, CEO of Curexa Pharmacy, said: “We have been very pleased with the collaboration and work from the QleanAir team and are excited to embark on this journey with them as a trusted business partner,” Taylor concluded.
